Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.

Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R.

Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25332. [Epub ahead of print] No abstract available.

PMID:
30370957
2.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
3.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P; French Belgian Swiss APL group.

Haematologica. 2018 Jul 19. pii: haematol.2018.198614. doi: 10.3324/haematol.2018.198614. [Epub ahead of print]

4.

Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing.

Dupuy A, Lemonnier F, Fataccioli V, Martin-Garcia N, Robe C, Pelletier R, Poullot E, Moktefi A, Mokhtari K, Rousselet MC, Traverse-Glehen A, Delarue R, Tournilhac O, Delfau-Larue MH, Haioun C, Ortonne N, Copie-Bergman C, de Leval L, Pujals A, Gaulard P.

J Mol Diagn. 2018 Sep;20(5):677-685. doi: 10.1016/j.jmoldx.2018.05.012. Epub 2018 Jul 5.

PMID:
29981867
5.

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.

Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, Marolleau JP, Oberic L, Le Du K, Fornecker LM, Tournilhac O, Veillard AS, Chaillol I, Robin M, Tamburini J, Brice P.

Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184. Epub 2018 Apr 2.

PMID:
29611187
6.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

7.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurran T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournilhac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Haematologica. 2018 Aug;103(8):e356-e359. doi: 10.3324/haematol.2017.182352. Epub 2018 Mar 8. No abstract available.

8.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
9.

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.

Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E.

Ann Oncol. 2018 Mar 1;29(3):715-723. doi: 10.1093/annonc/mdx787.

PMID:
29253087
10.

"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.

Chapiro E, Lesty C, Gabillaud C, Durot E, Bouzy S, Armand M, Le Garff-Tavernier M, Bougacha N, Struski S, Bidet A, Laharanne E, Barin C, Veronese L, Prié N, Eclache V, Gaillard B, Michaux L, Lefebvre C, Gaillard JB, Terré C, Penther D, Bastard C, Nadal N, Fert-Ferrer S, Auger N, Godon C, Sutton L, Tournilhac O, Susin SA, Nguyen-Khac F; GroupeFrancophone de Cytogénétique Hématologique(GFCH) and the French Innovative Leukemia Organization (FILO) group.

Am J Hematol. 2018 Mar;93(3):375-382. doi: 10.1002/ajh.24990. Epub 2017 Dec 18.

PMID:
29194741
11.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, de Latour RP.

Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.

12.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

13.

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group.

N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.

PMID:
28953447
14.

Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.

Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, Tournilhac O, Bachy E, Sonet A, Amorim S, Laurent C, Gaulard P, Tilly H, Sibon D.

Eur J Cancer. 2017 Sep;83:146-153. doi: 10.1016/j.ejca.2017.06.026. Epub 2017 Jul 20.

PMID:
28735072
15.

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, Cymbalista F.

Am J Hematol. 2017 Aug;92(8):E166-E168. doi: 10.1002/ajh.24773. Epub 2017 May 30. No abstract available.

16.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO).

Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10.

PMID:
28395585
17.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

18.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N.

J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.

PMID:
28129526
19.

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuaillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G, Apparailly F.

Haematologica. 2017 Apr;102(4):746-754. doi: 10.3324/haematol.2016.153189. Epub 2017 Jan 25.

20.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
21.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID:
27956157
22.

Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.

Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, Sirvent A, Plesa A, Salaun V, Béné MC, Bories D, Tournilhac O, Merle-Béral H, Leblond V, Le Garff-Tavernier M, Dhedin N.

Eur J Haematol. 2017 Apr;98(4):363-370. doi: 10.1111/ejh.12836. Epub 2017 Jan 30.

PMID:
27943415
23.

Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.

Le Bris Y, Struski S, Guièze R, Rouvellat C, Prade N, Troussard X, Tournilhac O, Béné MC, Delabesse E, Ysebaert L.

Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.

PMID:
27678008
24.

Telomere status in chronic lymphocytic leukemia with TP53 disruption.

Guièze R, Pages M, Véronèse L, Combes P, Lemal R, Gay-Bellile M, Chauvet M, Callanan M, Kwiatkowski F, Pereira B, Vago P, Bay JO, Tournilhac O, Tchirkov A.

Oncotarget. 2016 Aug 30;7(35):56976-56985. doi: 10.18632/oncotarget.10927.

25.

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G; From the Lymphoma Study Association (LYSA) centers.

Oncotarget. 2016 Dec 20;7(51):85573-85583. doi: 10.18632/oncotarget.10764.

26.

Aggressive skin cancers in patients who experienced chronic GvHD after allogeneic bone marrow transplantation.

Zampaolo AS, Kanold J, Tournilhac O, Franck F, Bachelerie M, D'Incan M.

Bone Marrow Transplant. 2017 Jan;52(1):130-131. doi: 10.1038/bmt.2016.187. Epub 2016 Jul 18. No abstract available.

PMID:
27427917
27.

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.

Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais JP, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P, de Leval L.

Blood. 2016 Sep 15;128(11):1490-502. doi: 10.1182/blood-2016-02-698977. Epub 2016 Jul 1.

28.

Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.

Souchet L, Levy V, Ouzegdouh M, Tamburini J, Delmer A, Dupuis J, Le Gouill S, Pégourié-Bandelier B, Tournilhac O, Boubaya M, Vargaftig J, Choquet S, Leblond V; FILO (French Innovative Leukemia Organization).

Am J Hematol. 2016 Aug;91(8):782-6. doi: 10.1002/ajh.24405. Epub 2016 Jun 3.

29.

Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.

Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillerm G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S.

Bone Marrow Transplant. 2016 Sep;51(9):1184-90. doi: 10.1038/bmt.2016.102. Epub 2016 Apr 25.

PMID:
27111043
30.

[Ibrutinib prescription in B-cell lymphoid neoplasms].

Dougé A, Ravinet A, Bay JO, Tournilhac O, Guièze R, Lemal R.

Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25. French.

PMID:
26822906
31.

Docosahexaenoic Acid Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells.

Guièze R, Gyan E, Tournilhac O, Halty C, Veyrat-Masson R, Akil S, Berger M, Hérault O, Callanan M, Bay JO.

Hematol Rep. 2015 Dec 17;7(4):6043. doi: 10.4081/hr.2015.6043. eCollection 2015 Nov 23.

32.

Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.

Cabannes-Hamy A, Lemal R, Goldwirt L, Poulain S, Amorim S, Pérignon R, Berger J, Brice P, De Kerviler E, Bay JO, Sauvageon H, Beldjord K, Mourah S, Tournilhac O, Thieblemont C.

Am J Hematol. 2016 Mar;91(3):E17-9. doi: 10.1002/ajh.24279. No abstract available.

33.

[Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].

Dupic G, Collangettes D, Dillies AF, Calvet L, Tournilhac O, Bay JO, Mahammedi H.

Bull Cancer. 2015 Dec;102(12):1010-9. doi: 10.1016/j.bulcan.2015.10.009. Epub 2015 Nov 19. Review. French.

PMID:
26607453
34.

TCL1 expression patterns in Waldenström macroglobulinemia.

Lemal R, Bard-Sorel S, Montrieul L, Bay JO, Ravinet A, Ledoux-Pilon A, Cagnard N, Bailly S, Morel P, Charlotte F, Leleu X, Poulain S, Déchelotte PJ, Hermine O, Leblond V, Tournilhac O, Guièze R.

Mod Pathol. 2016 Jan;29(1):83-8. doi: 10.1038/modpathol.2015.122. Epub 2015 Oct 23.

35.

[Natural history of portal cavernoma without liver disease. A single centre retrospective study of 32 cases].

Resseguier AS, André M, Orian Lazar EA, Bommelaer G, Tournilhac O, Delèvaux I, Ruivard M, D'Incan M, Boyer L, Aumaître O.

Rev Med Interne. 2016 Jun;37(6):394-8. doi: 10.1016/j.revmed.2015.07.017. Epub 2015 Sep 19. French.

PMID:
26387759
36.

Usefulness of EUS-guided fine needle aspiration biopsy in the diagnosis of suspected or recurring lymphoproliferative disorders.

Poincloux L, André M, Darcha C, Goutte M, Dapoigny M, Bommelaer G, Abergel A, Tournilhac O.

Surg Oncol. 2016 Dec;25(4):459-465. doi: 10.1016/j.suronc.2015.08.007. Epub 2015 Sep 3.

PMID:
26362342
37.

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Guièze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, Dilhuydy MS, Cabes M, Ysebaert L, Burns A, Nguyen-Khac F, Davi F, Véronèse L, Combes P, Le Garff-Tavernier M, Leblond V, Merle-Béral H, Alsolami R, Hamblin A, Mason J, Pettitt A, Hillmen P, Taylor J, Knight SJ, Tournilhac O, Schuh A.

Blood. 2015 Oct 29;126(18):2110-7. doi: 10.1182/blood-2015-05-647578. Epub 2015 Aug 27.

38.

[Chronic lymphocytic leukemia].

Lemal R, Tournilhac O.

Rev Prat. 2015 Jun;65(6):869-74. French. No abstract available.

PMID:
26298920
39.

Lenalidomide is safe and active in Waldenström macroglobulinemia.

Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X.

Am J Hematol. 2015 Nov;90(11):1055-9. doi: 10.1002/ajh.24175. Epub 2015 Oct 6.

40.

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.

Djelbani-Ahmed S, Chandesris MO, Mekinian A, Canioni D, Brouzes C, Hanssens K, Pop G, Durieu I, Durupt S, Grosbois B, Besnard S, Tournilhac O, Beyne-Rauzy O, Agapé P, Delmer A, Ranta D, Jeandel PY, Georgin-Lavialle S, Frenzel L, Damaj G, Eder V, Lortholary O, Hermine O, Fain O, Soussan M.

Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2013-20. doi: 10.1007/s00259-015-3117-3. Epub 2015 Jul 5.

PMID:
26140850
41.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
42.

Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets.

de Leval L, Parrens M, Le Bras F, Jais JP, Fataccioli V, Martin A, Lamant L, Delarue R, Berger F, Arbion F, Bossard C, Copin MC, Canioni D, Charlotte F, Damaj G, Dartigues P, Fabiani B, Ledoux-Pilon A, Montagne K, Molina T, Patey M, Tas P, Peoch M, Petit B, Petrella T, Picquenot JM, Rousset T, Rousselet MC, Soubeyran I, Thiebault S, Tournilhac O, Xerri L, Gisselbrecht C, Haioun C, Delsol G, Gaulard P.

Haematologica. 2015 Sep;100(9):e361-4. doi: 10.3324/haematol.2015.126300. Epub 2015 Jun 4. No abstract available.

43.

[Intraocular lymphoma associated with primary malignant lymphoma of the central nervous system: Seven-year experience of a tertiary center].

Joubert R, Bonnin N, Kemeny JL, Moluçon-Chabrot C, Tournilhac O, Bacin F, Chiambaretta F.

J Fr Ophtalmol. 2015 Jun;38(6):559-66. doi: 10.1016/j.jfo.2015.03.005. Epub 2015 May 11. French.

44.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

45.

Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).

Bourgne C, Janel A, Berger J, Rapatel C, Tournilhac O, Hermet E, Guerci A, Lioret F, Briançon A, Bamdad M, Boiret-Dupré N, Berger MG.

Leuk Res. 2015 Mar;39(3):329-34. doi: 10.1016/j.leukres.2014.11.014. Epub 2014 Dec 13.

PMID:
25612940
46.

Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Dartigeas C, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Apr 14;5:10. doi: 10.1186/s40164-016-0038-1. eCollection 2015.

47.

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Mar 1;5:7. doi: 10.1186/s40164-016-0036-3. eCollection 2015. Erratum in: Exp Hematol Oncol. 2015;5:10.

48.

[Plasma cell leukemia].

Ravinet A, Bay JO, Tournilhac O.

Bull Cancer. 2014 Nov;101(11):1048-58. doi: 10.1684/bdc.2014.2048. Review. French.

PMID:
25418598
49.

90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.

Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N.

Ann Oncol. 2015 Jan;26(1):193-8. doi: 10.1093/annonc/mdu503. Epub 2014 Oct 30.

PMID:
25361987
50.

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, Delorenzi M, Gaulard P, de Leval L.

Blood. 2014 Nov 6;124(19):2983-6. doi: 10.1182/blood-2014-07-584953. Epub 2014 Sep 15.

Supplemental Content

Loading ...
Support Center